AC
LKFT

Apogem Capital’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Apogem Capital’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-14,300
Closed -$887K – 174
2022
Q1 		$887K Sell
14,300
-1,300
-8% -$79.6K 0.61% 52
2021
Q4 		$860K Buy
15,600
+7,900
+103% +$412K 0.56% 64
2021
Q3 		$405K Buy
+7,700
New +$457K 0.26% 125

Other funds holding LKFT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Apogem Capital's LKFT Position: Q4 2022 in Review

Apogem Capital sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q4 2022, closing a stake of 28,584 shares — an estimated $1.22M sold.

Apogem Capital first reported a position in LKFT in Q1 2021 and held it in 7 quarters. The position peaked at $1.71M in Q1 2022. 75 funds tracked by Wall St. Rank hold LKFT as of Q4 2022.

  • Apogem Capital reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q4 2022 after selling out during the quarter.
  • Apogem Capital sold 28,584 Lakefront Biotherapeutics American Depositary Shares shares in Q4 2022, an estimated $1.22M.
  • Apogem Capital first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q1 2021 and held it in 7 quarters.
  • Apogem Capital's Lakefront Biotherapeutics American Depositary Shares position peaked at $1.71M in Q1 2022.
  • 75 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q4 2022.

Based on Apogem Capital's 13F filing for Q4 2022, filed 13 Feb 2023.